Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking effective targeted therapies, with circular RNAs (circRNAs) emerging as key regulators in cancer progression through competitive endogenous RNA (ceRNA) networks. Although circRNAs function as miRNA sponges in TNBC, the specific role of circDUSP1 in the miR-429/DLC1 pathway remains unknown. In this study, a circular RNA, circDUSP1, was identified as differentially expressed in TNBC using an online database. Using TNBC patient tissues and cell lines (MDA-MB-231/MDA-MB-468), we quantified circDUSP1 expression via qRT-PCR. The molecular characteristics of circDUSP1 were identified through methods such as nuclear-cytoplasmic separation, RNase R digestion, and FISH. Assessed the impact of circDUSP1 on TNBC cell proliferation/migration/invasion through functional assays (CCK-8, colony formation, Transwell, etc.). The circDUSP1/miR-429/DLC1 regulatory network's role in TNBC was validated using dual-luciferase reporter gene, RNA pull-down, and rescue assays. circDUSP1 was significantly downregulated in TNBC tissues and cell lines. circDUSP1 overexpression suppressed TNBC cell proliferation, migration, invasion, and tumor growth in vivo circDUSP1 directly bound miR-429 to relieve its repression of tumor suppressor DLC1 miR-429 mimics attenuated circDUSP1-mediated tumor suppression. circDUSP1 inhibits TNBC progression by acting as a molecular sponge for miR-429 to upregulate DLC1. This regulatory network represents a novel therapeutic target for TNBC.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12276224PMC
http://dx.doi.org/10.1038/s41598-025-11621-7DOI Listing

Publication Analysis

Top Keywords

tnbc
10
circdusp1
9
circdusp1/mir-429/dlc1 regulatory
8
regulatory network
8
proliferation migration
8
migration invasion
8
triple-negative breast
8
breast cancer
8
circdusp1 identified
8
tissues cell
8

Similar Publications

Interferon-induced senescent CD8 T cells reduce anti-PD1 immunotherapy efficacy in early triple-negative breast cancer.

Sci Transl Med

September 2025

Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Precision Cancer Medicine Center, Fudan University Shanghai Cancer Center, Shanghai 200032, P. R. China.

Triple-negative breast cancers (TNBCs) lack predictive biomarkers to guide immunotherapy, especially during early-stage disease. To address this issue, we used single-cell RNA sequencing, bulk transcriptomics, and pathology assays on samples from 171 patients with early-stage TNBC receiving chemotherapy with or without immunotherapy. Our investigation identified an enriched subset of interferon (IFN)-induced CD8 T cells in early TNBC samples, which predict immunotherapy nonresponsiveness.

View Article and Find Full Text PDF

Triple-negative breast cancer (TNBC) is a particularly aggressive subtype of breast cancer with high metastatic potential, limited treatment options, and low patient survival rates. By combining functional proteomics and genomics approaches, we identified an oncogenic transcriptional network in mesenchymal and invasive TNBC involving the glucocorticoid receptor (GR), GATA6, MYC, and AP-1 transcription factors. Although these transcription factors bound extensively to shared enhancers, they utilized different enhancer repertoires from this shared enhancer pool to drive distinct downstream oncogenic pathways.

View Article and Find Full Text PDF

Background: The roles of long non-coding RNAs (lncRNAs) in the progression of various human tumors have been extensively studied. However, their specific mechanisms and therapeutic potential in Triple-Negative Breast Cancer (TNBC) remain to be fully elucidated.

Materials And Methods: The qRT-PCR assay was utilized to assess the relative mRNA levels of TFAP2A-AS1, PHGDH, and miR-6892.

View Article and Find Full Text PDF

Purpose: Advanced, pre-treated TNBC has a dismal prognosis and lacks effective options beyond standard cytotoxics. We previously showed, via phosphoproteomic screening, that CDK6 and ERK hyperactivation are linked to adverse outcomes and represent actionable targets. This prompted us to evaluate palbociclib and binimetinib in advanced TNBC after one or two prior therapies.

View Article and Find Full Text PDF

PRMT1-Mediated PARP1 Methylation Drives Lung Metastasis and Chemoresistance via P65 Activation in Triple-Negative Breast Cancer.

Research (Wash D C)

September 2025

State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.

Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype, characterized by a high propensity for metastasis, poor prognosis, and limited treatment options. Research has demonstrated a substantial correlation between the expression of protein arginine N-methyltransferase 1 (PRMT1) and enhanced proliferation, metastasis, and poor outcomes in TNBC. However, the specific role of PRMT1 in lung metastasis and chemoresistance remains unclear.

View Article and Find Full Text PDF